VRDN
Viridian Therapeutics Inc.
$19.55
+$0.12(+0.62%)
81
Overall
--
Value
81
Tech
--
Quality
Market Cap
$1.59B
Volume
607.26K
52W Range
$9.90 - $27.20
Target Price
$39.47
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $2.5M | $3.5M | $4.0M | $8.4M | -- | $1.1M | $3.0M | $1.8M | $314.0K | $302.0K | ||
| Total Revenue | $2.5M | $3.5M | $4.0M | $8.4M | -- | $1.1M | $3.0M | $1.8M | $314.0K | $302.0K | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $-2.5M | $-2.5M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $66.0K | $3.5M | $4.0M | -- | -- | $1.1M | $3.0M | $1.8M | $314.0K | $302.0K | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $11.4M | $-20.5M | $-30.5M | $-41.5M | $46.4M | $111.4M | $82.7M | $136.1M | $254.8M | $299.3M | ||
| Research & Development | $1.0M | $13.7M | $19.6M | $30.4M | $34.8M | $98.2M | $56.9M | $100.9M | $159.8M | $238.3M | ||
| Research Expense | $1.0M | $13.7M | $19.6M | $30.4M | $34.8M | $98.2M | $56.9M | $100.9M | $159.8M | $238.3M | ||
| Selling, General & Administrative | $10.3M | $6.8M | $10.9M | $11.0M | $11.6M | $13.3M | $25.8M | $35.2M | $95.0M | $61.1M | ||
| Selling & Marketing Expenses | $2.6M | $1.7M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| General & Administrative Expenses | $7.7M | $6.8M | $10.9M | $11.0M | $11.6M | $13.3M | $25.8M | $35.2M | $95.0M | $61.1M | ||
| Salaries & Wages | $-3.0M | $-198.0K | $-2.4M | $-3.7M | $-4.0M | -- | -- | -- | $67.2M | $42.1M | ||
| Depreciation & Amortization | -- | $-300.0K | $-300.0K | $-300.0K | $-300.0K | $200.0K | $100.0K | $300.0K | $500.0K | $500.0K | ||
| Depreciation & Amortization | -- | $-300.0K | $-300.0K | $-300.0K | $-300.0K | $200.0K | $100.0K | $300.0K | $500.0K | $500.0K | ||
| Amortization | -- | -- | -- | -- | -- | $300.0K | $500.0K | $500.0K | $800.0K | $700.0K | ||
| Other Operating Expenses | $141.0K | $166.0K | -- | -- | $-300.0K | $300.0K | -- | -- | $254.8M | $299.3M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-11.3M | $-17.0M | $-30.5M | $-41.5M | $-46.4M | $-110.4M | $-79.7M | $-134.3M | $-254.4M | $-299.0M | ||
| EBITDA | $-11.1M | $-16.9M | $-26.2M | $-32.8M | $-42.0M | $-110.0M | $-79.3M | $-129.1M | $-236.9M | $-269.0M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $141.0K | $95.0K | -- | -- | -- | $508.0K | $3.0K | $486.0K | $1.8M | -- | ||
| Intinc | -- | $39.0K | $403.0K | $1.3M | $941.0K | -- | $318.0K | $4.9M | $18.6M | $32.1M | ||
| Net Non-Operating Interest Income/Expense | $-141.0K | $-287.0K | $20.0K | $381.0K | $106.0K | $-508.0K | $315.0K | $4.4M | $18.6M | $32.1M | ||
| Gain on Sale of Securities | -- | -- | -- | -- | $3.0K | -- | $4.0K | -- | $700.0K | -- | ||
| Other Income/Expense | -- | $-3.0K | $-4.0M | $-8.4M | $-4.5M | $-173.0K | $96.0K | -- | $-519.0K | -- | ||
| Other Special Charges | -- | $3.0K | $4.0M | $8.4M | $4.5M | $173.0K | $318.0K | -- | $-181.0K | -- | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | -- | $2.0M | -- | -- | $-2.0M | $300.0K | -- | -- | -- | -- | ||
| Special Income Charges | -- | $-2.8M | -- | -- | $2.0M | $-300.0K | -- | -- | -- | -- | ||
| Impairment of Capital Assets | -- | $797.0K | -- | -- | -- | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-11.3M | $-17.3M | $-26.5M | $-32.7M | $-41.9M | $-110.2M | $-79.4M | $-129.4M | $-237.7M | $-269.9M | ||
| Pre-Tax Income | $-11.5M | $-17.3M | $-26.5M | $-32.7M | $-41.9M | $-110.7M | $-79.4M | $-129.9M | $-235.9M | $-269.9M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $277.0K | $193.0K | -- | -- | -- | -- | -- | -- | -- | -- | ||
| NET INCOME | ||||||||||||
| Net Income | $-11.5M | $-17.3M | $-26.5M | $-32.7M | $-41.9M | $-110.7M | $-79.4M | $-129.9M | $-237.7M | $-269.9M | ||
| Net Income (Continuing Operations) | $-11.5M | $-17.3M | $-26.5M | $-32.7M | $-41.9M | $-110.7M | $-79.4M | $-129.9M | $-237.7M | $-269.9M | ||
| Net Income (Discontinued Operations) | $-11.5M | $-17.3M | $-26.5M | $-32.7M | $-41.9M | $-110.7M | $-79.4M | $-129.9M | $-237.7M | $-269.9M | ||
| Net Income (Common Stockholders) | $-11.5M | $-17.3M | $-26.5M | $-32.7M | $-41.9M | $-110.7M | $-79.4M | $-129.9M | $-237.7M | $-269.9M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-264.2M | ||
| TOTALS | ||||||||||||
| Total Expenses | $8.9M | $20.5M | $-30.5M | $-41.5M | $46.4M | $111.4M | $82.7M | $136.1M | $254.8M | $299.3M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $539.5K | $614.0K | $19.2M | $29.6M | $2.1M | $3.6M | $11.9M | $32.1M | $44.8M | -- | ||
| Average Shares Outstanding (Diluted) | $545.6K | $612.3K | $19.2M | $29.7M | $2.1M | $3.6M | $11.9M | $32.1M | $44.8M | -- | ||
| Shares Outstanding | $10.7M | $21.4M | $30.2M | $30.9M | $53.1M | $7.2M | $25.9M | $42.9M | $62.8M | $81.5M | ||
| Basic EPS | -- | -- | -- | -- | -- | $-31.13 | $-6.66 | $-4.05 | $-5.31 | $-3.07 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | -- | $-31.13 | $-6.66 | $-4.05 | $-5.31 | -- | ||
| Diluted EPS | $-21.02 | $-28.21 | $-1.38 | $-1.1 | $-20.04 | $-31.13 | $-6.66 | $-4.05 | $-5.31 | $-3.07 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | $-20.04 | -- | $-6.66 | $-4.05 | $-5.31 | -- | ||
| OTHER METRICS | ||||||||||||
| Accretion On Preferred Stock | -- | $49.0K | $5.0K | -- | -- | -- | -- | -- | -- | -- | ||
| Accrued Preferred Stock Dividends | -- | -- | -- | -- | -- | $110.7M | $79.4M | -- | -- | -- | ||
| Gain On Sale Of P P E | -- | -- | -- | -- | -- | -- | $-100.0K | -- | -- | -- | ||
| Other Gand A | $7.7M | $6.8M | $10.9M | $11.0M | $11.6M | $13.3M | $25.8M | $35.2M | $95.0M | $61.1M | ||
| Otherunder Preferred Stock Dividend | -- | $49.0K | $5.0K | -- | -- | $110.7M | $79.4M | -- | -- | -- | ||
| Preferred Stock Dividends | -- | $49.0K | $5.0K | -- | -- | $110.7M | $79.4M | -- | -- | -- | ||
| Rent And Landing Fees | $7.7M | $6.8M | $10.9M | $11.0M | -- | -- | -- | -- | -- | -- | ||
| Selling Expense | $2.6M | $1.7M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Restruct | -- | $2.0M | -- | -- | $-2.0M | $300.0K | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | VRDN | $19.55 | +0.6% | 607.26K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Viridian Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW